Abstract 1173P
Background
Acral melanoma (AM) is the most common subtype of Chinese melanoma population, taking up over 50%-60%. Compared to cutaneous melanoma, AM is lack of frequent driven mutation like BRAF alternation which only occurs around 10%. Meanwhile, 10%-15% of AM can harbor NRAS mutation. This single-center retrospective study aims to investigate the survival impact of NRAS mutant status on Chinese AM after receiving radical surgery.
Methods
We retrospectively collected AM patients who received radical surgery in Fudan University Shanghai Center with confirmative genomic information from 2017 to 2021. Information of clinicopathologic factors and recurrence and survival outcomes was retrieved from patients document database of our hospital.
Results
Totally 317 patients were recruited in our study.170 (53.6%) were males and median age was 62 years old (range 26-89). 281 (88.6%) cases had primary lesion at lower extremity. The mean Breslow thickness were 3.9mm and ulceration rate was 65.9%. According to AJCC 8th staging system, there were 12% Stage I, 32.2% Stage II and 55.8% Stage III. Genomic alternation occured included 71(22.4%) NRAS, 36 (11.4%) BRAF, 33 (10.4%) KIT and the other 177 (55.8%) widetype of these three genes. No statistical difference was observed in most of clinicopathologic factors between NRAS-mut and NRAS-wt patients. However, NRAS-mut group had higher risk of nodal metastasis beyond 1st tier basin (42.3% vs 27.2, P<0.002).With median follow-up of 22 months, NRAS-mut patients had significantly worse relapse-free survival (RFS, P<0.0001) and overall survival (OS, P=0.010). Distant metastasis-free survival (DMFS) was also numerically reduced but not reached significance (P=0.074). Multivariate analysis showed NRAS mutation was an independent prognostic factors for both RFS (P=0.008) and OS (P=0.025).Among patients receiving adjuvant anti-PD1 monotherapy, median RFS time was significantly worse for NRAS-mut patients (9 months vs 26 months, P<0.0001).
Conclusions
In conclusion, AM harboring NRAS mutation had higher risk of relapse and death as well as reduced efficacy of adjuvant anti-PD1 monotherapy compared to NRAS-wt after radical surgery. NRAS mutation was an independent prognostic factor for resectable Chinese AM population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was funded by Shanghai Science and Technology Development Funds, grant number 9411951700; LinGang laboratory “Seeking Distinguished Young Scholars” project, grant number LG-QS-202205-11; National Natural Science Foundation of China, grant number 81802636.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1149P - Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment
Presenter: Lisanne Zijlker
Session: Poster session 13
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13